Is the DAS28 score the most adequate method to estimate activity in rheumatoid arthritis? Clinimetric considerations and simulations scenarios;¿Es la puntuación DAS28 el método más adecuado para estimar la actividad de la artritis reumatoide? Consideraciones clinimétricas y escenarios de simulación

Reumatologia Clinica

Volumn 4, Issue 5, 2008, Pages 183-190

  Belmonte Serrano, Miguel Ángel ^a  

^a HOSPITAL GENERAL DE CASTELLÓN   (Spain)

Author keywords

Activity assessment; Clinical scenarios; Clinimetrics; DAS28; Rheumatoid arthritis; Sensitivity analysis; Severity of illness index; Simulation; Therapeutic decision

Indexed keywords

ARTHRALGIA; ARTICLE; DISEASE ACTIVITY; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; JOINT SWELLING; MEDICAL DECISION MAKING; METHODOLOGY; ORGAN WEIGHT; REMISSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SENSITIVITY ANALYSIS; TREATMENT PLANNING;

EID: 54549105808     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/S1699-258X(08)72462-8     Document Type: Article

References (15)

1. Van Riel PL, Fransen J. DAS28: a useful instrument to monitor infliximab treatment in patients with rheumatoid arthritis. Arthritis Res Ther. 2005;7:189-90.
2. Vander Cruyssen B, Van Looy S, Wyns B, Westhovens R, Durez P, Van den Bosch F, et al. DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment. Arthritis Res Ther. 2005;7:R1063-71.
3. Van der Heijde DM, Van 't Hof M, Van Riel PL, Van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol. 1993;20:579-81.
4. Fuchs HA. The use of the Disease Activity Score in the analysis of clinical trials in rheumatoid arthritis. J Rheumatol. 1993;20:1863-6.
5. Fuchs HA, Brooks R, Callahan LF, Pincus T. A simplified twenty-eight-joint quantitative articular index in rheumatoid arthritis. Arthritis Rheum. 1989;32:531-7.
6. Smolen JS, Breedveld FC, Eberl G, Jones I, Leeming M, Wylie GL, et al. Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis. Arthritis Rheum. 1995;38:38-43.
7. Prevoo ML, Van't Hof MA, Kuper HH, Van Leeuwen MA, Van de Putte LB, Van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44-8.
8. Van der Heijde DM. The original "DAS" and the "DAS28" are not interchangeable. Arthritis Rheum. 1998;41:942-5.
9. Prevoo ML, Van Gestel AM, Van't Hof MA, Van Rijswijk MH, Van de Putte LB, Van Riel PL. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the Disease Activity Score. Br J Rheumatol. 1996;35:1101-5.
10. Balsa A, Carmona L, Gonzalez Alvaro I, Belmonte Serrano MA, Tena X, Sanmartí R. Value of Disease Activity Score 28 (DAS28) and DAS28-3 compared to American College of Rheumatology-defined remission in rheumatoid artritis. J Rheumatol. 2004;31:40-6.
11. Van Riel PL, Van Gestel AM, Van de Putte LB. Development and validation of response criteria in rheumatoid arthritis: steps towards an international consensus on prognostic markers. Br J Rheumatol. 1996;35 Suppl 2:4-7.
12. Rodríguez-Valverde V, Cáliz-Caliz R, Alvaro-Gracia A, Marenco de la Fuente JL, Mulero Mendoza J, Tornero Molina J, et al. III actualización del consenso de la SER sobre terapia biológica en la artritis reumatoide. Reumatol Clin. 2006;2 Supl 2:S52-9.
13. Guidelines for the use of biologic therapies in rheumatoid arthritis. December 2006 update. Acta Reumatol Port. 2006;32:37-41.
14. Makinen H, Kautiainen H, Hannonen P, Mottonen T, Korpela M, Leirisalo-Repo M, et al. Disease Activity Score 28 as an instrument to measure disease activity in patients with early rheumatoid arthritis. J Rheumatol. 2007;34:1987-91.
15. Wolfe F, Michaud K, Pincus T, Furst D, Keystone E. The disease activity score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic: discordance between assessment measures and limitations in questionnaire use for regulatory purposes. Arthritis Rheum. 2005;52:3873-9.